Welcome to our dedicated page for Vaxcyte news (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.
Vaxcyte, Inc. reports clinical-stage vaccine developments focused on bacterial diseases, led by pneumococcal conjugate vaccine candidates in its PCV franchise. Recurring updates cover VAX-31 clinical studies in adult and infant populations, earlier PCV candidates including VAX-24 and VAX-XL, and pipeline programs such as VAX-A1 for Group A Strep and VAX-GI for Shigella.
Company news also addresses the XpressCF cell-free protein synthesis platform licensed from Sutro Biopharma, manufacturing and commercial-readiness activities, equity financings, quarterly financial results, and healthcare conference participation. These releases tie Vaxcyte’s vaccine engineering platform to clinical progress, supply-chain development, and capital resources supporting its pipeline.
Vaxcyte (Nasdaq: PCVX), a clinical-stage vaccine innovation company, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.
Interested parties can access a live webcast of the discussion through the Investors & Media section of Vaxcyte's website at http://investors.vaxcyte.com. For those unable to attend the live event, a replay of the webcast will be available for approximately 30 days following the conference.
This presentation offers an opportunity for investors and analysts to gain insights into Vaxcyte's progress in developing high-fidelity vaccines aimed at protecting against bacterial diseases.
Vaxcyte (Nasdaq: PCVX) has successfully closed its previously announced public offering, raising approximately $1.5 billion in gross proceeds. The offering included 12,087,378 shares of common stock at $103.00 per share and pre-funded warrants to purchase 2,427,184 shares at $102.999 per warrant. Underwriters fully exercised their option to purchase an additional 1,893,203 shares. The offering was managed by several prominent financial institutions, including BofA Securities, Jefferies, and Leerink Partners. Vaxcyte, a clinical-stage vaccine innovation company, plans to use the funds to advance its high-fidelity vaccines aimed at protecting against bacterial diseases.
Vaxcyte (Nasdaq: PCVX) has announced the pricing of a $1.3 billion public offering of common stock and pre-funded warrants. The company is selling 10,194,175 shares of common stock at $103.00 per share and 2,427,184 pre-funded warrants at $102.999 each. The exercise price for the warrants is $0.001 per share. Vaxcyte has granted underwriters a 30-day option to purchase up to 1,893,203 additional shares. The offering is expected to close on September 6, 2024. Major financial institutions are acting as joint book-running managers for the offering.
Vaxcyte (Nasdaq: PCVX), a clinical-stage vaccine innovation company, has announced the commencement of a $1.0 billion underwritten public offering of its common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional $150.0 million of shares. BofA Securities, Jefferies, Leerink Partners, Goldman Sachs & Co. , Evercore ISI, Guggenheim Securities, and Mizuho are acting as joint book-running managers for the offering. The offering is subject to market conditions, and its completion, size, and terms are not guaranteed. A shelf registration statement has been filed with the SEC, and a preliminary prospectus supplement and accompanying prospectus will be available on the SEC's website.
Vaxcyte (NASDAQ: PCVX) announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, in adults aged 50 and older. The study demonstrated robust immune responses for all 31 serotypes at all doses, with middle and high doses meeting or exceeding regulatory immunogenicity criteria. VAX-31 showed a safety profile similar to Prevnar 20® and was well-tolerated. Based on these results, Vaxcyte has selected VAX-31 to advance to an adult Phase 3 program, with plans to initiate a pivotal, non-inferiority study by mid-2025 and announce topline data in 2026. The company also plans to initiate a VAX-31 infant Phase 2 study in Q1 2025 for the pediatric indication.
Vaxcyte (Nasdaq: PCVX) announced a webcast and conference call on September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1/2 study of VAX-31, their 31-valent pneumococcal conjugate vaccine (PCV) candidate. The study evaluated the safety, tolerability, and immunogenicity of VAX-31 in healthy adults aged 50 and older. VAX-31 is designed to prevent invasive pneumococcal disease (IPD). Interested parties can participate via phone (800-225-9448 domestic, 203-518-9708 international) using conference ID PCVX0903 or through a live webcast on Vaxcyte's investor relations page. The webcast will be archived for 30 days after the event.
Vaxcyte (PCVX) reported Q2 2024 financial results and provided a business update. Key highlights include:
- VAX-31 adult Phase 1/2 study topline data expected in September 2024
- VAX-24 infant Phase 2 study topline data expected by Q1 2025
- $1.9 billion in cash and investments as of June 30, 2024
- R&D expenses increased to $131.5 million in Q2 2024
- Net loss widened to $128.7 million in Q2 2024
The company plans to advance either VAX-24 or VAX-31 to Phase 3 in adults following the VAX-31 data readout. Vaxcyte also appointed John Furey to its Board of Directors and received a $9.5 million NIAID grant for Chlamydia vaccine development.
Vaxcyte has appointed John Furey to its Board of Directors, effective July 2, 2024. Furey brings extensive experience in the biopharmaceutical and vaccine sectors, especially in the manufacture, supply, and commercialization of pneumococcal conjugate vaccines (PCVs). This addition comes as Vaxcyte advances its PCV candidates, VAX-24 and VAX-31, towards late-stage clinical development. Furey's expertise is expected to provide strategic insights and strengthen the company’s efforts in developing innovative vaccines using a cell-free technology platform.
Vaxcyte, Inc. (Nasdaq: PCVX) reported Q1 2024 financial results, highlighting completion of enrollment for VAX-31 Adult Phase 1/2 study and VAX-24 Infant Phase 2 study. They expect data by Q3 2024 and Q1 2025 respectively. The company had $1.9 billion in cash as of March 31, 2024, following a successful $816.5 million public offering in February. The company is progressing its PCV franchise and early-stage pipeline, focusing on preventing bacterial diseases.
Summary not available.